{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:33:07Z","timestamp":1779305587266,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.schres.2025.12.008","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T12:05:03Z","timestamp":1766145903000},"page":"3-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Treatment of schizotypal disorder: A systematic review and GRADE evaluation of the certainty of evidence"],"prefix":"10.1016","volume":"288","author":[{"given":"Kristina Ballestad","family":"Gundersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Arnfred","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai","family":"Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas Ros\u00e9n","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f8rn H.","family":"Ebdrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Polari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barnaby","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise Birkedal","family":"Glenth\u00f8j","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2025.12.008_bb0005","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.schres.2016.10.013","article-title":"Course of illness in a sample of patients diagnosed with a schizotypal disorder and treated in a specialized early intervention setting. Findings from the 3.5year follow-up of the OPUS II study","volume":"182","author":"Albert","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2025.12.008_bb0010","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"3","key":"10.1016\/j.schres.2025.12.008_bb0015","doi-asserted-by":"crossref","first-page":"378","DOI":"10.11124\/JBIES-23-00268","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies","volume":"22","author":"Barker","year":"2024","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.schres.2025.12.008_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.116223","article-title":"Excess mortality and suicide risk in treatment-seeking individuals with schizotypal disorder: a population-based study using Swedish national registers","volume":"342","author":"Berge","year":"2024","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2025.12.008_bb0025","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 7: considering bias and conflicts of interest among the included studies","volume":"Vol. n 6.5","author":"Boutron","year":"2024"},{"issue":"4","key":"10.1016\/j.schres.2025.12.008_bb0030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1037\/prj0000429","article-title":"Assessment and treatment planning for schizotypal personality disorder: a metacognitively oriented point of view","volume":"43","author":"Cheli","year":"2020","journal-title":"Psychiatr. Rehabil. J."},{"issue":"3","key":"10.1016\/j.schres.2025.12.008_bb0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/pmh.1447","article-title":"Metacognitively oriented psychotherapy for schizotypal personality disorder: a two-case series","volume":"13","author":"Cheli","year":"2019","journal-title":"Personal. Ment. Health"},{"issue":"1","key":"10.1016\/j.schres.2025.12.008_bb0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12888-023-04610-5","article-title":"A pilot randomized controlled trial comparing a novel compassion and metacognition approach for schizotypal personality disorder with a combination of cognitive therapy and psychopharmacological treatment","volume":"23","author":"Cheli","year":"2023","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2025.12.008_bb0045","first-page":"1","article-title":"An evolutionarily informed therapy for adolescents with prominent schizotypal traits: a pilot five case series","author":"Cheli","year":"2023","journal-title":"Psychosis"},{"key":"10.1016\/j.schres.2025.12.008_bb0050","doi-asserted-by":"crossref","DOI":"10.1037\/per0000732","article-title":"Psychosocial and pharmacological interventions for cluster A personality disorders: a systematic review and two exploratory meta-analyses","author":"Cheli","year":"2025","journal-title":"Personality Disord. Theory Res. Treat."},{"issue":"7","key":"10.1016\/j.schres.2025.12.008_bb0055","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ajmg.b.32166","article-title":"Taiwan schizophrenia linkage study: lessons learned from endophenotype-based genome-wide linkage scans and perspective","volume":"162b","author":"Chen","year":"2013","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.schres.2025.12.008_bb0060","author":"Covidence systematic review software"},{"issue":"4","key":"10.1016\/j.schres.2025.12.008_bb0065","doi-asserted-by":"crossref","first-page":"420","DOI":"10.5195\/jmla.2018.345","article-title":"The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review","volume":"106","author":"Eriksen","year":"2018","journal-title":"J. Med. Libr. Assoc."},{"issue":"1","key":"10.1016\/j.schres.2025.12.008_bb0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamapsychiatry.2013.269","article-title":"The psychosis high-risk state: a comprehensive state-of-the-art review","volume":"70","author":"Fusar-Poli","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2025.12.008_bb0075","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamapsychiatry.2019.4779","article-title":"Prevention of psychosis: advances in detection, prognosis, and intervention","volume":"77","author":"Fusar-Poli","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2025.12.008_bb0080","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1001\/archpsyc.1986.01800070070009","article-title":"Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo","volume":"43","author":"Goldberg","year":"1986","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2025.12.008_bb0085","series-title":"A Dimensional Approach to Schizotypy: Conceptualization and Treatment","first-page":"315","article-title":"Clinical staging of schizotypal disorder: preliminary considerations and treatment implications","author":"Gundersen","year":"2023"},{"issue":"11","key":"10.1016\/j.schres.2025.12.008_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-075140","article-title":"Treatment of schizotypal disorder: a protocol for a systematic review of the evidence and recommendations for clinical practice","volume":"13","author":"Gundersen","year":"2023","journal-title":"BMJ Open"},{"issue":"7650","key":"10.1016\/j.schres.2025.12.008_bb0095","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2025.12.008_bb0100","doi-asserted-by":"crossref","first-page":"s49","DOI":"10.1192\/bjp.187.48.s49","article-title":"Clinical characteristics of first-admitted patients with ICD-10 schizotypal disorder","volume":"48","author":"Handest","year":"2005","journal-title":"Br. J. Psychiatry Suppl."},{"key":"10.1016\/j.schres.2025.12.008_bb0105","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2024"},{"issue":"4","key":"10.1016\/j.schres.2025.12.008_bb0110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0010-440X(86)90001-5","article-title":"Neuroleptic treatment of schizotypal personality disorders","volume":"27","author":"Hymowitz","year":"1986","journal-title":"Compr. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2025.12.008_bb0115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-0447.1989.tb09238.x","article-title":"An open, noncomparative study of amoxapine in borderline disorders","volume":"79","author":"Jensen","year":"1989","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2025.12.008_bb0120","author":"Joanna Briggs Institute"},{"issue":"1","key":"10.1016\/j.schres.2025.12.008_bb0125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.schres.2003.12.008","article-title":"Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder","volume":"71","author":"Keshavan","year":"2004","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2025.12.008_bb0130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41537-018-0062-8","article-title":"Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review","volume":"4","author":"Kirchner","year":"2018","journal-title":"NPJ Schizophr."},{"issue":"2","key":"10.1016\/j.schres.2025.12.008_bb0135","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41380-021-01359-9","article-title":"Cortical and subcortical neuroanatomical signatures of schizotypy in 3004 individuals assessed in a worldwide ENIGMA study","volume":"27","author":"Kirchner","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2025.12.008_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(00)00059-1","article-title":"Physostigmine and cognition in schizotypal personality disorder","volume":"48","author":"Kirrane","year":"2001","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2025.12.008_bb0145","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4088\/JCP.v64n0602","article-title":"Risperidone in the treatment of schizotypal personality disorder","volume":"64","author":"Koenigsberg","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2025.12.008_bb0150","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.schres.2017.03.001","article-title":"Social cognition psychometric evaluation (SCOPE) in people with early psychosis: a preliminary study","volume":"190","author":"Ludwig","year":"2017","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2025.12.008_bb0155","doi-asserted-by":"crossref","first-page":"109","DOI":"10.31887\/DCNS.2006.8.1\/smarder","article-title":"The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia","volume":"8","author":"Marder","year":"2006","journal-title":"Dialogues Clin. Neurosci."},{"issue":"8","key":"10.1016\/j.schres.2025.12.008_bb0160","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1176\/ajp.148.8.1064","article-title":"Fluoxetine in the treatment of borderline and schizotypal personality disorders","volume":"148","author":"Markovitz","year":"1991","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2025.12.008_bb0165","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.biopsych.2006.06.034","article-title":"The effects of guanfacine on context processing abnormalities in schizotypal personality disorder","volume":"61","author":"McClure","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2025.12.008_bb0170","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/npp.2010.5","article-title":"Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum","volume":"35","author":"McClure","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.schres.2025.12.008_bb0175","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1176\/appi.ajp.2018.18030349","article-title":"Guanfacine augmentation of a combined intervention of computerized cognitive remediation therapy and social skills training for schizotypal personality disorder","volume":"176","author":"McClure","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2025.12.008_bb0180","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1037\/h0041029","article-title":"Schizotaxia, schizotypy, schizophrenia","volume":"17","author":"Meehl","year":"1962","journal-title":"Am. Psychol."},{"issue":"6","key":"10.1016\/j.schres.2025.12.008_bb0185","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1038\/s41380-025-02902-8","article-title":"Preventing psychosis in people at clinical high risk: an updated meta-analysis by the world psychiatric association preventive psychiatry section","volume":"30","author":"Minichino","year":"2025","journal-title":"Mol. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2025.12.008_bb0190","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.schres.2025.12.008_bb0195","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.neubiorev.2016.10.034","article-title":"Insights to the schizophrenia continuum: a systematic review of saccadic eye movements in schizotypy and biological relatives of schizophrenia patients","volume":"72","author":"Myles","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"6","key":"10.1016\/j.schres.2025.12.008_bb0200","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/cpp.2901","article-title":"Psychotherapy for patients with schizotypal personality disorder: a scoping review","volume":"30","author":"Nielsen","year":"2023","journal-title":"Clin. Psychol. Psychother."},{"issue":"1","key":"10.1016\/j.schres.2025.12.008_bb0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2006.01.002","article-title":"Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment","volume":"83","author":"Nordentoft","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2025.12.008_bb0210","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2025.12.008_bb0215","series-title":"Personality Disorders","article-title":"Cluster A personality disorders: a review","author":"Parnas","year":"2005"},{"key":"10.1016\/j.schres.2025.12.008_bb0220","article-title":"Comorbidity of obsessive-compulsive disorder and schizotypal personality disorder: clinical response and treatment resistance to pharmacotherapy in a 3-year follow-up naturalistic study [original research]","volume":"10","author":"Perris","year":"2019","journal-title":"Front. Psych."},{"key":"10.1016\/j.schres.2025.12.008_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2024.104142","article-title":"Clinical high-risk for psychosis (CHR-P) circa 2024: synoptic analysis and synthesis of contemporary treatment guidelines","volume":"100","author":"Poletti","year":"2024","journal-title":"Asian J. Psychiatr."},{"issue":"2","key":"10.1016\/j.schres.2025.12.008_bb0230","first-page":"53","article-title":"Prevalence, correlates, disability, and comorbidity of DSM-IV schizotypal personality disorder: results from the wave 2 national epidemiologic survey on alcohol and related conditions","volume":"11","author":"Pulay","year":"2009","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.schres.2025.12.008_bb0235","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.nicl.2016.05.019","article-title":"Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism","volume":"11","author":"Rabella","year":"2016","journal-title":"NeuroImage: Clinical"},{"issue":"6","key":"10.1016\/j.schres.2025.12.008_bb0240","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1176\/ajp.110.6.406","article-title":"Dynamics and classification of disorderd behavior","volume":"110","author":"Rado","year":"1953","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2025.12.008_bb0245","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/npp.2014.192","article-title":"Effects of the D1 dopamine receptor agonist Dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder","volume":"40","author":"Rosell","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.schres.2025.12.008_bb0250","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.eurpsy.2015.01.013","article-title":"EPA guidance on the early intervention in clinical high risk states of psychoses","volume":"30","author":"Schmidt","year":"2015","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2025.12.008_bb0255","author":"Sch\u00fcnemann"},{"issue":"11","key":"10.1016\/j.schres.2025.12.008_bb0260","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1176\/ajp.141.11.1455","article-title":"Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol","volume":"141","author":"Serban","year":"1984","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.schres.2025.12.008_bb0265","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0920-9964(95)00002-X","article-title":"D-amphetamine challenge effects on Wisconsin card sort test. Performance in schizotypal personality disorder","volume":"20","author":"Siegel","year":"1996","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2025.12.008_bb0270","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2025.12.008_bb0275","series-title":"Risk and Protective Factors in Schizophrenia. Towards a Conceptual Model of the Disease Process","first-page":"29","article-title":"Genotype-environment interaction in the Finnish adoptive family study. Interplay between genes and environment?","author":"Tienari","year":"2002"},{"key":"10.1016\/j.schres.2025.12.008_bb0280","series-title":"JBI Manual for Evidence Synthesis","article-title":"Systematic reviews of effectiveness (2020)","author":"Tufanaru","year":"2024"},{"key":"10.1016\/j.schres.2025.12.008_bb0285","series-title":"International Statistical Classification of Diseases and Related Health Problems","author":"World Health Organization","year":"2019"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425004268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425004268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T23:46:10Z","timestamp":1770335170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996425004268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":57,"alternative-id":["S0920996425004268"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2025.12.008","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of schizotypal disorder: A systematic review and GRADE evaluation of the certainty of evidence","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2025.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}